The drug is designed to improve progression-free survival. The approval was based on demonstration of improved progression-free survival in a multicenter, international, randomized, double-blind, placebo-controlled study.
Safety data was also evaluated. The most commonly reported adverse reactions in lanreotide-treated patients were abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, among others.
More articles on gastroenterology:
Dr. Sonia Kupfer meets with National Institute of Diabetes and Digestive and Kidney Diseases
Newman Regional Health to acquire $345k endoscopy system
New EndoChoice slim scope, US Endoscopy distribution agreement & more – 6 GI/endoscopy company key notes
